AMAG Pharma (AMAG) Reports Q1 Loss Per Share of $1.59, Raises FY Revenue Guidance
Tweet
Share
E-mailGet Alerts AMAG Hot Sheet
Price: $13.75 --0%
Financial Fact:
Total costs and expenses: 105.02M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Total costs and expenses: 105.02M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
AMAG Pharma (NASDAQ: AMAG) reported Q1 EPS of ($1.59), may not compare to the analyst estimate of ($0.54). Revenue for the quarter came in at $146.4 million versus the consensus estimate of $151.79 million.
GUIDANCE:
AMAG Pharma sees FY2018 revenue of $540-580 million, versus the consensus of $541.8 million.
For earnings history and earnings-related data on AMAG Pharma (AMAG) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c
- Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
